Literature DB >> 24870972

MicroRNAs in the pathogenesis of myelodysplastic syndromes and myeloid leukaemia.

Su Jung Song1, Pier Paolo Pandolfi.   

Abstract

PURPOSE OF REVIEW: This review highlights recent insights into the roles of microRNAs (miRNAs) in pathogenesis of myeloid malignancies and tantalising prospects of miRNA therapy. RECENT
FINDINGS: New roles for miRNAs in biological and disease processes are constantly being discovered. Although great effort has been put into identifying and cataloguing aberrantly expressed miRNAs in leukaemia, very little is known about the functional consequences of their deregulation in myeloid malignancies. This review will discuss the significance of powerful oncogenic miRNAs such as miR-22 in self-renewal and transformation of haematopoietic stem cells, as well as their ability to induce epigenetic alterations in the pathogenesis of the stem cell disorder myelodysplastic syndromes and myeloid leukaemia.
SUMMARY: Improved understanding of biological roles of miRNAs in the pathogenesis of haematological malignancies will allow rational stratification of patients and provide new therapeutic entries for the treatment of myelodysplastic syndromes and leukaemia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24870972      PMCID: PMC4113208          DOI: 10.1097/MOH.0000000000000054

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  58 in total

1.  Silencing of hsa-miR-124 by EVI1 in cell lines and patients with acute myeloid leukemia.

Authors:  Iria Vázquez; Miren Maicas; Nerea Marcotegui; Ana Conchillo; Elisabet Guruceaga; José Roman-Gomez; María J Calasanz; Xabier Agirre; Felipe Prosper; María D Odero
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-07       Impact factor: 11.205

2.  A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia.

Authors:  Maria Chiara Di Bernardo; Dalemari Crowther-Swanepoel; Peter Broderick; Emily Webb; Gabrielle Sellick; Ruth Wild; Kate Sullivan; Jayaram Vijayakrishnan; Yufei Wang; Alan M Pittman; Nicola J Sunter; Andrew G Hall; Martin J S Dyer; Estella Matutes; Claire Dearden; Tryfonia Mainou-Fowler; Graham H Jackson; Geoffrey Summerfield; Robert J Harris; Andrew R Pettitt; Peter Hillmen; David J Allsup; James R Bailey; Guy Pratt; Chris Pepper; Chris Fegan; James M Allan; Daniel Catovsky; Richard S Houlston
Journal:  Nat Genet       Date:  2008-08-31       Impact factor: 38.330

3.  Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.

Authors:  Guido Marcucci; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Tamara Vukosavljevic; Peter Paschka; Susan P Whitman; Christian Langer; Claudia D Baldus; Chang-Gong Liu; Amy S Ruppert; Bayard L Powell; Andrew J Carroll; Michael A Caligiuri; Jonathan E Kolitz; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

4.  Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer.

Authors:  Tindara Franchina; Valeria Amodeo; Giuseppe Bronte; Giuseppina Savio; Giuseppina R R Ricciardi; Maria Picciotto; Antonio Russo; Antonio Giordano; Vincenzo Adamo
Journal:  J Cell Physiol       Date:  2014-01       Impact factor: 6.384

5.  An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

Authors:  Dan Rohle; Janeta Popovici-Muller; Nicolaos Palaskas; Sevin Turcan; Christian Grommes; Carl Campos; Jennifer Tsoi; Owen Clark; Barbara Oldrini; Evangelia Komisopoulou; Kaiko Kunii; Alicia Pedraza; Stefanie Schalm; Lee Silverman; Alexandra Miller; Fang Wang; Hua Yang; Yue Chen; Andrew Kernytsky; Marc K Rosenblum; Wei Liu; Scott A Biller; Shinsan M Su; Cameron W Brennan; Timothy A Chan; Thomas G Graeber; Katharine E Yen; Ingo K Mellinghoff
Journal:  Science       Date:  2013-04-04       Impact factor: 47.728

6.  MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia.

Authors:  Ramiro Garzon; Stefano Volinia; Chang-Gong Liu; Cecilia Fernandez-Cymering; Tiziana Palumbo; Flavia Pichiorri; Muller Fabbri; Kevin Coombes; Hansjuerg Alder; Tatsuya Nakamura; Neal Flomenberg; Guido Marcucci; George A Calin; Steven M Kornblau; Hagop Kantarjian; Clara D Bloomfield; Michael Andreeff; Carlo M Croce
Journal:  Blood       Date:  2008-01-10       Impact factor: 22.113

Review 7.  MicroRNAs: key regulators of stem cells.

Authors:  Vamsi K Gangaraju; Haifan Lin
Journal:  Nat Rev Mol Cell Biol       Date:  2009-02       Impact factor: 94.444

8.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

Authors:  Wei Xu; Hui Yang; Ying Liu; Ying Yang; Ping Wang; Se-Hee Kim; Shinsuke Ito; Chen Yang; Pu Wang; Meng-Tao Xiao; Li-xia Liu; Wen-qing Jiang; Jing Liu; Jin-ye Zhang; Bin Wang; Stephen Frye; Yi Zhang; Yan-hui Xu; Qun-ying Lei; Kun-Liang Guan; Shi-min Zhao; Yue Xiong
Journal:  Cancer Cell       Date:  2011-01-18       Impact factor: 38.585

9.  Characterization of human plasma-derived exosomal RNAs by deep sequencing.

Authors:  Xiaoyi Huang; Tiezheng Yuan; Michael Tschannen; Zhifu Sun; Howard Jacob; Meijun Du; Meihua Liang; Rachel L Dittmar; Yong Liu; Mingyu Liang; Manish Kohli; Stephen N Thibodeau; Lisa Boardman; Liang Wang
Journal:  BMC Genomics       Date:  2013-05-10       Impact factor: 3.969

10.  Serum microRNAs are promising novel biomarkers.

Authors:  Shlomit Gilad; Eti Meiri; Yariv Yogev; Sima Benjamin; Danit Lebanony; Noga Yerushalmi; Hila Benjamin; Michal Kushnir; Hila Cholakh; Nir Melamed; Zvi Bentwich; Moshe Hod; Yaron Goren; Ayelet Chajut
Journal:  PLoS One       Date:  2008-09-05       Impact factor: 3.240

View more
  5 in total

1.  Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted "hsa-miR-2278" as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A.

Authors:  Burçin Tezcanlı Kaymaz; Nur Selvi Günel; Metin Ceyhan; Vildan Bozok Çetintaş; Buket Özel; Melis Kartal Yandım; Sezgi Kıpçak; Çağdaş Aktan; Aysun Adan Gökbulut; Yusuf Baran; Buket Kosova Can
Journal:  Tumour Biol       Date:  2015-05-08

Review 2.  The microRNA feedback regulation of p63 in cancer progression.

Authors:  Changwei Lin; Xiaorong Li; Yi Zhang; Yihang Guo; Jianyu Zhou; Kai Gao; Jing Dai; Gui Hu; Lv Lv; Juan Du; Yi Zhang
Journal:  Oncotarget       Date:  2015-04-20

Review 3.  MicroRNA, an Antisense RNA, in Sensing Myeloid Malignancies.

Authors:  Stephanie Rebecca Setijono; Hyog Young Kwon; Su Jung Song
Journal:  Front Oncol       Date:  2018-01-30       Impact factor: 6.244

4.  miR-194-5p/BCLAF1 deregulation in AML tumorigenesis.

Authors:  C Dell'Aversana; C Giorgio; L D'Amato; G Lania; F Matarese; S Saeed; A Di Costanzo; V Belsito Petrizzi; C Ingenito; J H A Martens; I Pallavicini; S Minucci; A Carissimo; H G Stunnenberg; L Altucci
Journal:  Leukemia       Date:  2017-02-20       Impact factor: 11.528

5.  Astaxanthin inhibits proliferation and induces apoptosis of LX‑2 cells by regulating the miR‑29b/Bcl‑2 pathway.

Authors:  Shanshan Zhu; Tao Wang; Fei Luo; Huawen Li; Qing Jia; Taiping He; Hongfu Wu; Tangbin Zou
Journal:  Mol Med Rep       Date:  2019-03-14       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.